A5075872698- Hemophilia Treatment and Research
- Blood Coagulation and Thrombosis Mechanisms
- Platelet Disorders and Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hemostasis and retained surgical items
- Heparin-Induced Thrombocytopenia and Thrombosis
- Blood properties and coagulation
- Antiplatelet Therapy and Cardiovascular Diseases
- Protease and Inhibitor Mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- Chronic Myeloid Leukemia Treatments
- Medical Research and Treatments
- Cervical Cancer and HPV Research
- Bacterial Infections and Vaccines
- Vaccine Coverage and Hesitancy
- Blood groups and transfusion
- Monoclonal and Polyclonal Antibodies Research
- Atrial Fibrillation Management and Outcomes
- Hepatitis B Virus Studies
- Therapeutic Uses of Natural Elements
- Hepatitis Viruses Studies and Epidemiology
- Odor and Emission Control Technologies
- melanin and skin pigmentation
- Travel-related health issues
Nara Medical University
2016-2025
Osaka National Hospital
2023-2025
National Institute of Technology, Gifu College
2017
University of Rochester
2012-2013
Fairfax Neonatal Associates
2010
We previously identified a factor (F)VIII molecular defect associated with an R2159C mutation in the C1 domain (named "FVIII-Ise") together undetectable FVIII antigen (FVIII:Ag) levels measured by two-site sandwich ELISA using anti-C2 alloantibody (alloAb). The patient had clinically mild hemophilia A, and his reduced FVIII:C correlated FVIII:Ag monoclonal antibodies (mAbs) A2 A2/B epitopes, suggesting that modified C2 antigenicity. To investigate functional structural characteristics of...
Factor VIIIa functions as a cofactor for factor IXa in the phospholipid surface-dependent activation of X. Both C2 domain and Gla are involved binding required In this study, we have examined close relationship between these domains Xase complex. Enzyme-linked immunosorbent assay-based surface plasmon resonance-based assays absence showed that Glu-Gly-Arg active site-modified bound to immobilized recombinant (rC2) dose-dependently (Kd = 108 nm). This ability was optimal under physiological...
Factor V (FV) plays pivotal roles in both procoagulant and anticoagulant mechanisms. Genetic mutations, FV-W1920R (FVNara) FV-A2086D (FVBesançon), the C1 C2 domains of FV light chain, respectively, seem to be associated with deep vein thrombosis. However, detailed mechanism(s) through which these mutations are linked thrombophilia remains fully explored. The aim this study was clarify thrombotic presence abnormalities. Full-length wild-type (WT) mutated were prepared using stable, human cell...
Factor (F) VIII functions as a cofactor in FXase, markedly accelerating the rate of FIXa-catalyzed activation FX. Earlier work identified FX-binding site having μM affinity within COOH-terminal region FVIIIa A1 subunit. In present study, surface plasmon resonance (SPR), ELISA-based binding assays, and chemical cross-linking were employed to assess an interaction between FX FVIII light chain (A3C1C2 domains). SPR assays showed that LC bound immobilized (K(d) = 165 370 nM, respectively)....
Protein S functions as an activated protein C (APC)-independent anticoagulant in the inhibition of intrinsic factor X activation, although precise mechanisms remain to be fully investigated. In present study, diminished VIIIa/factor IXa-dependent independent APC, a functional Xa generation assay. The presence resulted c. 17-fold increase K(m) for IXa with VIIIa Xase complex, but twofold decrease X. Surface plasmon resonance-based assays showed that VIII, particularly A2 and A3 domains, bound...
Emicizumab prophylaxis improves coagulation function in congenital hemophilia A, regardless of inhibitor presence. We recently reported that emicizumab enhanced the coagulant potentials, ex vivo, plasmas from patients with acquired A (PwAHAs) at diagnosis. However, effects PwAHAs during clinical course remain unclear. To assess vivo course. Blood samples were obtained 14 on (median) days 0 and 6 a severe-bleeding phase, 27 59 reduced-bleeding phase elevated endogenous factor VIII (FVIII)...
Prothrombin complex concentrates (PCC) have been used as bypassing agents for the treatment of haemophilia A patients with inhibitor well replacement therapy in congenital and acquired deficiencies vitamin-K-dependent clotting factors. The efficacy PCC is variable, however, especially during long-term high-dose use, all currently available products this nature contain heparin. We examined haemostatic properties using reconstituted whole blood made by mixing coagulation-factor-deficient...
Abstract Factor VIII (FVIII) functions as a cofactor of FIXa for FX activation in the intrinsic tenase complex. The 1811-1818 region FVIII A3 domain was observed to contribute binding, and K1813A/K1818A mutant increased binding affinity FIXa. current study aims identify mutated protein(s) that increase FVIIIa activity region. mutants with K1813A, K1818A, were expressed baby hamster kidney cells followed by assessments using purified global coagulation assays mouse models hemophilia A (HA)....
We have recently reported that plasmin likely associates with the factor VIII light chain to proteolyze at Lys36 within A1 domain. In this study, we determined rate of plasmin-catalyzed inactivation on forms VIIIa containing A1-(1–336) and 1722A3C1C2, reflecting cleavage, was reduced by ∼60%, compared those 1649A3C1C2 1690A3C1C2. SDS-PAGE analysis revealed cleavage 1722A3C1C2 markedly slower than Surface plasmon resonance-based assays, using active site-modified anhydro-plasmin (Ah-plasmin)...